C3orf18 Inhibitors
Chemical inhibitors of C3orf18 function through various biochemical mechanisms to diminish the activity of this protein, which is implicated in cellular processes such as growth, proliferation, and stress responses. Rapamycin, a known mTORC1inhibitor, indirectly reduces C3orf18 activity by diminishing protein synthesis, crucial for cell growth that C3orf18 may facilitate. Similarly, LY 294002 and PD 98059 target the PI3K/AKT/mTOR and MAPK pathways, respectively, both essential for cell proliferation and survival, thus potentially reducing C3orf18 activity. WZB117 and 2-Deoxy-D-glucose interfere with cellular energy production by inhibiting GLUT1 and hexokinase, respectively, leading to a decrease in ATP and reduced energy-dependent processes in which C3orf18 might be involved. Bortezomib disrupts protein degradation pathways, which could lead to cell cycle arrest or apoptosis, thereby indirectly decreasing C3orf18 activity if it is related to cell viability. Further, SB 203580's inhibition of p38 MAPK and the DNA-damaging effect of Mitomycin C could lead to reduced stress response or cell cycle arrest, potentially diminishing C3orf18's role in these processes.
Additionally, Triptolide's broad-spectrum inhibition of transcription factors and U0126's targeting of MEK1/2 could lead to a reduction in cellular processes that may involve C3orf18. Geldanamycin's binding to Hsp90 disrupts the proper folding of proteins, which could destabilize C3orf18 if it is Hsp90-dependent. Lastly, Sulforaphane suppresses the NF-κB pathway, which is implicated in cell survival, thus potentially inhibiting C3orf18 activity if the protein operates within this pathway. These chemical inhibitors, through their targeted action on specific cellular pathways and processes, offer a diverse approach to indirectly reducing the functional activity of C3orf18 without directly targeting its transcription, translation, or general activation mechanisms, but rather by influencing the biochemical pathways that C3orf18 is potentially involved in.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTORC1, a complex that positively regulates protein synthesis. C3orf18 is implicated in cell growth and proliferation. Inhibition of mTORC1 by Rapamycin would reduce protein synthesis and thus, indirectly diminish C3orf18 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 is an inhibitor of PI3K, which is part of the PI3K/AKT/mTOR signaling pathway. By inhibiting PI3K, it leads to decreased AKT phosphorylation and activation, thereby reducing downstream signaling that could indirectly lead to a decrease in C3orf18 activity. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 inhibits glucose transporter 1 (GLUT1), leading to a reduction in glycolysis and cellular energy production. Since C3orf18 is associated with cell growth, diminished glycolysis would potentially reduce the cellular resources necessary for C3orf18's activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a potent inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. Inhibition of MEK leads to reduced ERK activation, which may play a role in cell cycle progression. A decrease in ERK activity could lead to indirect inhibition of C3orf18 function. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose acts as a glycolysis inhibitor by inhibiting hexokinase. This leads to a decrease in ATP production, which is critical for many cellular processes. Reduced energy levels would likely decrease the functional activity of C3orf18 by limiting cellular growth. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. By disrupting proteasomal activity, it can lead to decreased proliferation and increased apoptosis, which could indirectly decrease the activity of C3orf18 by reducing cell viability. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is an inhibitor of p38 MAPK, which is involved in stress responses and apoptosis. Inhibition of p38 MAPK could lead to decreased cellular stress responses, potentially reducing the activity of C3orf18 if it is involved in these cellular processes. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C is a DNA crosslinking agent, which can lead to DNA damage and cell cycle arrest. If C3orf18 is involved in cell cycle regulation, the induction of cell cycle arrest by Mitomycin C would indirectly inhibit the activity of C3orf18. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide inhibits multiple transcription factors and cellular processes related to proliferation and apoptosis. By altering transcription and promoting apoptosis, Triptolide could indirectly reduce C3orf18 activity if it is involved in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2 in the MAPK pathway, which is crucial for cell proliferation and differentiation. By inhibiting MEK1/2, U0126 could indirectly lead to decreased C3orf18 activity, especially if C3orf18 is implicated in these cellular processes. | ||||||